Coherus Oncology, Inc. (CHRS) vs Neuronetics, Inc. (STIM)
A side-by-side comparison of Coherus Oncology, Inc. and Neuronetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.03HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
STIM
Neuronetics, Inc.
$2.23HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT
Total return — CHRS vs STIM
growth of $100 · dividends reinvested · last 8yCHRS -92.3% (-27.4%/yr)STIM -92.1% (-27.2%/yr)STIM compounded faster over this window
CHRS STIM
CHRS vs STIM: by the numbers
- •CHRS is the larger company ($159M vs $155M market cap).
- •Both run net losses; STIM's is the smaller (-19.62% vs -257.10% net margin).
- •STIM grew revenue faster over the past five years (23.26% vs -33.60% CAGR).
Metrics side by side
Valuation
| Metric | CHRS | STIM |
|---|---|---|
| P/S ratio | 3.12 | 1.00 |
| P/B ratio | 2.62 | 8.69 |
Profitability
| Metric | CHRS | STIM |
|---|---|---|
| Gross margin | 63.55% | 49.12% |
| Operating margin | -425.72% | -14.74% |
| Net margin | -257.10% | -19.62% |
| ROE | -215.26% | -170.49% |
| ROIC | -135.38% | -22.15% |
Growth (annualized)
| Metric | CHRS | STIM |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 23.26% |
| Total return CAGR (5Y) | -41.38% | -19.46% |
Frequently asked
- Which has grown faster, CHRS or STIM?
- Over the past five years, STIM grew revenue faster — CHRS at a -33.60% CAGR versus STIM at 23.26%.
- How have CHRS and STIM total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and STIM delivered -19.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Coherus Oncology ROENeuronetics ROECoherus Oncology operating marginNeuronetics operating marginCoherus Oncology revenue growthNeuronetics revenue growthCoherus Oncology free cash flowNeuronetics free cash flow
Coherus Oncology & Neuronetics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.